CN Patent

CN118339144A — 卡博替尼共晶及制备方法以及作为药物或在药物制剂中的应用

Assigned to Medoncare Pharmaceutical Co ltd · Expires 2024-07-12 · 2y expired

What this patent protects

涉及卡博替尼的共晶体、其制备方法以及它作为药物或在药物制剂中的应用，更特别是用于治疗进展性转移甲状腺髓样癌(MTC)、肾癌、前列腺癌的应用。所述共晶体具有良好的溶解度、较好的稳定性和工艺可开发性等，且制备的方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

涉及卡博替尼的共晶体、其制备方法以及它作为药物或在药物制剂中的应用，更特别是用于治疗进展性转移甲状腺髓样癌(MTC)、肾癌、前列腺癌的应用。所述共晶体具有良好的溶解度、较好的稳定性和工艺可开发性等，且制备的方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN118339144A
Jurisdiction: CN
Classification: —
Expires: 2024-07-12
Drug substance claim: No
Drug product claim: No
Assignee: Medoncare Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.